ImageneBio (IMA) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
INmune Bio (INMB) has outperformed ImageneBio (IMA) over the past year, losing 5.1% versus a loss of 44.7%. Over five years, INMB leads with a -90.0% price change compared with -96.8% for IMA. ImageneBio is the larger company by market cap ($52.4 million vs $51.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMA | INMB |
|---|---|---|
| Share price | $4.61 | $1.86 |
| Market cap | $52.43M | $51.62M |
| 1-day change | -1.91% | -0.53% |
| YTD return | -33.19% | +19.23% |
| 1-year return | -44.72% | -5.10% |
| 5-year return | -96.83% | -90.01% |
| EPS (TTM) | $-4.09 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.10 | $2.60 |
| 52-week low | $3.94 | $1.09 |
| Distance from 52-week high | -49.34% | -28.46% |
| Average volume | 12.98K | 421.24K |
| Shares outstanding | 11.37M | 27.75M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed IMA by 39.6 percentage points over the past year.
IMA vs INMB FAQ
Which is bigger, ImageneBio or INmune Bio?
ImageneBio (IMA) is larger, with a market capitalization of $52.43M compared with $51.62M for INmune Bio (INMB).
Which stock has performed better over the past year, IMA or INMB?
INMB returned -5.10% over the past 12 months, compared with -44.72% for IMA (price return, excluding dividends). Past performance does not predict future results.
Are ImageneBio and INmune Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.